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Abstract
Background: The relationship between the brain and the immune system has become increasingly topical as, although
it is immune-specialised, the CNS is not free from the influences of the immune system. Recent data indicate
that peripheral immune stimulation can significantly affect the CNS. But the mechanisms underpinning this relationship
remain unclear. The standard approach to understanding this relationship has relied on systemic immune activation
using bacterial components, finding that immune mediators, such as cytokines, can have a significant effect on brain
function and behaviour. More rarely have studies used disease models that are representative of human disorders.
Methods: Here we use a well-characterised animal model of psoriasis-like skin inflammation—imiquimod—to investigate
the effects of tissue-specific peripheral inflammation on the brain. We used full genome array, flow cytometry analysis of
immune cell infiltration, doublecortin staining for neural precursor cells and a behavioural read-out exploiting natural
burrowing behaviour.
Results: We found that a number of genes are upregulated in the brain following treatment, amongst which is a subset
of inflammatory chemokines (CCL3, CCL5, CCL9, CXCL10, CXCL13, CXCL16 and CCR5). Strikingly, this model induced the
infiltration of a number of immune cell subsets into the brain parenchyma, including T cells, NK cells and myeloid cells,
along with a reduction in neurogenesis and a suppression of burrowing activity.
Conclusions: These findings demonstrate that cutaneous, peripheral immune stimulation is associated with
significant leukocyte infiltration into the brain and suggest that chemokines may be amongst the key mediators
driving this response.
Keywords: Peripheral inflammation, Chemokines, Neuroinflammation, Leukocyte infiltration, Burrowing behaviour,
Neurogenesis
Background
Neuropsychiatric disorders, including depression, anxiety
and schizophrenia, are a significant and growing burden
to society [1] and are also commonly associated with
chronic inflammatory disorders [2]. However, we know
very little about the mechanisms underpinning this
relationship.
Increasingly compelling data have highlighted possible
roles for a number of immune mediators, including
inflammatory cytokines, in the pathogenesis of neuro-
psychiatric disorders. Examples include (a) treatment of
hepatitis C with IFN-α results in the onset of major de-
pressive disorder (MDD) in around 50 % of patients and
is the most common reason for ceasing treatment [3–5],
(b) the treatment of psoriasis patients with the anti-TNF
drug etanercept improved the clinical symptoms of de-
pression independently of an improvement in psoriatic
disease score in patients [6, 7] and (c) patients suffering
from long-term MDD or schizophrenia have an elevated
inflammatory profile [8, 9]. In essence these pathology-,
or therapy-, associated depressive episodes represent exag-
gerated presentations of the so-called ‘sickness behaviour’,
which is a recognised and normal response typically
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associated with microbial infection. Nonetheless, despite
these correlations, it remains unclear how inflammation
in the periphery relates to neuropsychiatric phenotypes.
One family of cytokines that might play a key role in
this communication pathway is the chemotactic cyto-
kine, or chemokine, family. The classical role of chemo-
kines is in mediating cell trafficking and inflammatory
chemokines are important for cell migration during im-
mune and inflammatory responses [10]. Many chemo-
kines, such as CXCL12, are expressed in the brain in
steady-state and play an important role in development
and homeostasis [11]. However, some inflammatory che-
mokines are also expressed in the brain and are upregu-
lated during infection [12, 13]. We hypothesised that, in
systemic inflammatory disease contexts, brain-expressed
chemokines would drive immune cell infiltration into
the brain, leading to the activation of local cells resulting
in co-morbid psychiatric disorders [14–16].
To test this hypothesis, we used a well-characterised
mouse model of skin inflammation. The topical applica-
tion of Aldara™, a commercially available drug which
contains the Toll-like receptor (TLR) 7/8 ligand imiqui-
mod (IMQ), to the dorsal skin of mice, causes a psoriasis-
like skin pathology. The ease and reproducibility of this
model made it ideal for our study [17, 18]. Here, we show
that peripheral skin inflammation can induce a ‘remote’
chemokine response in the brain that appears to be main-
tained independently of a response in the periphery. In
addition, we show that this is associated with leukocyte in-
filtration into the brain parenchyma, a reduction in neural
precursor cells in the dentate gyrus of the hippocampus
and behavioural alterations reflected in a suppression of
burrowing behaviour. These findings highlight the impact
of peripheral immune stimulation on homeostatic CNS
function and implicate chemokines and their receptors as
potential therapeutic targets for chronic inflammatory
disease associated neuropsychiatric co-morbidities.
Methods
Mice
Wild-type C57BL/6 female mice (6- to 8-week old,
16–20 g) were purchased from Harlan Laboratories.
Mice were maintained in specific pathogen-free condi-
tions in the Central Research Facility at the University
of Glasgow. All experiments received ethical approval
and were performed under the auspices of UK Home
Office Licence.
Models of inflammation
Several models of peripheral inflammation were used in
this study. These included the topical application of a
cream containing the TLR7/8 ligand IMQ (Aldara model),
the topical application of a sterile inflammatory agent
(TPA), the topical application of IMQ in the absence of
active components in the Aldara vehicle (Topical IMQ)
and the intraperitoneal administration of IMQ (soluble
IMQ). The four models are described in detail below.
Since three out of the four models were used to induce
cutaneous inflammation, this study focused on female
mice, as it has been shown that male mice respond dif-
ferently to topically applied inflammatory agents [19].
(i) Aldara model of skin inflammation
Mice were shaved on their dorsal skin 24 h prior to
Aldara treatment. Eighty milligrams of 5 %
imiquimod (Aldara™, MEDA Ab, Stockholm,
Sweden) cream, or aqueous control cream, was
applied to the shaved dorsal every 24 h for 1, 3 or
5 days. Mice were euthanised 24 h following the
final application.
(ii) Topically applied IMQ model
In accordance with manufacturer’s instructions,
soluble IMQ (Source BioScience, Nottingham, UK)
was reconstituted in PBS prior to being dissolved in
aqueous control cream. Mice were shaved on their
dorsal skin 24 h prior to treatment. Eighty milligrams
of 5 % IMQ cream, or aqueous control cream, was
applied every 24 h for 5 days. Mice were euthanised
24 h following the final application.
(iii) Soluble IMQ injection model
Soluble IMQ was reconstituted in PBS to a
concentration of 1 mg/ml. Mice were injected,
intraperitoneally, with 100 μl IMQ (100 μg) or PBS
every 24 h for 5 days. Mice were euthanised 24 h
following the final application.
(iv) TPA model of inflammation
Mice were shaved on their dorsal skin 24 h prior to
treatment. One hundred fifty microlitres of 100 μM
12-O-tetradecanoylphorbol-13-acetate (TPA)
(Sigma Aldrich, Missouri, USA), or an equal volume
of acetone control (Sigma-Aldrich, Missouri, USA),
was applied to the mice every 24 h for 1, 3 or
5 days. Mice were euthanised 24 h after the
final application.
Cardiac perfusion of animal tissues
Prior to tissue retrieval, all mice were extensively per-
fused as follows: the right atrium of the heart was cut to
allow blood to drain into the chest cavity without com-
promising the circulation. Perfusions were performed by
injecting with 20 ml of PBS, warmed to 37 °C, into the
left ventricle of the beating heart using a 23G needle.
RNA isolation from brain tissue and peripheral blood
leukocytes
Brain tissue was ‘snap-frozen’ and stored at −80 °C until
use. Under RNase-free conditions, brains were homoge-
nised using the TissueLyser LT (Qiagen, Hilden, Germany).
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RNA was extracted from homogenised tissue using QIAzol®
Lysis Reagent (Qiagen, Hilden, Germany), isolated RNA
was further purified and genomic DNA was removed, using
an RNeasy Mini Kit (Qiagen, Hilden, Germany). Red blood
cells were lysed from blood samples using red blood cell
lysis buffer (Miltenyi, Cologne, Germany). Cells were first
passed through a QIAshredder (Qiagen, Hilden, Germany)
before RNA was isolated from peripheral blood leukocytes
(PBL) using an RNeasy Mini Kit.
GeneChip microarray analysis
Microarray analyses were performed in the Glasgow
Polyomics Facility at the University of Glasgow
(www.polyomics.gla.ac.uk), as previously described
[20]. Briefly, 1 μg of purified total RNA was amplified
by in vitro transcription and converted to sense-
strand complementary DNA (cDNA) using a WT
Expression kit (Life Technologies, California, USA).
Fragmented and labelled cDNA samples were hybri-
dised to GeneChip Mouse Gene 1.0 ST Arrays
(Affymetrix, California, USA). Procedures were carried
out as described by the manufacturers. Microarray
profiling data were deposited in the National Center
for Biotechnology Information Gene Expression
Omnibus database with the series entry identifier
GSE72214 and can be accessed using the following
link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=sbmpmemufzynhmj&acc=GSE72214.
Data generated using GeneSpring GX software were
normalised using RMA 16. Normalised data were ana-
lysed using unpaired t tests to determine the significance
of each gene in Aldara-treated mice compared to control
mice. p values were adjusted for multiple comparisons
using the Benjamini Hochberg multiple comparison test.
Gene ontology terms were assigned to differentially
expressed genes using the Database for Annotation, Visua-
lization and Integrated Discovery (DAVID) Bioinformatics
Resources v6.7 (http://david.abcc.ncifcrf.gov/). Analysis
was performed in accordance with two protocols out-
lined by Huang et al. [21, 22]. The significance of en-
richment was determined using a modified Fisher’s
exact test. A Benjamini-Hochberg multiple comparison
test was used to correct for the rate of type I errors. Co-
expression of a gene cluster was considered significant if it
satisfied a p value cutoff of 0.05.
QRT-PCR
Total RNA was reverse transcribed using Quantitect®
Reverse Transcription kit (Qiagen, Hilden, Germany)
with random primers. Quantitative real-time PCR (QRT-
PCR) amplifications were performed in triplicate using
PerfeCTa® SYBR® Green FastMix® (Quanta Biosystems,
Maryland, USA). Primers were designed using Primer3
Input software (version 0.4.0) and generated by IDT
Technologies. Primer sequences are listed in Additional
file 1: Table S1. A 750-nM mix of forward and reverse
primers was used per reaction. QPCR reactions were
performed using a Prism® 7900HT Sequence Detection
System (Life Technologies, California, USA) for 40 cy-
cles in accordance with manufacturer’s guidelines. The
absolute copy number was calculated from a standard
curve and normalised to the housekeeping gene, TATA-
binding protein (TBP), as previously described [23].
Fold-change values were calculated by comparing the
normalised copy number of individual samples to the
mean of the control samples.
Luminex
Blood was collected by cardiac puncture. Plasma was
isolated from whole blood by centrifugation. Plasma
concentrations of soluble inflammatory mediators were
determined using mouse multiplex cytokine Luminex
panel kits (Life Technologies, California, USA) in ac-
cordance with manufacturer’s instructions.
Generation of a single-cell suspension from brain tissue
Perfused brains were extracted from control and treated
mice as described. Brains were digested for 45 min at
37°, 750 rpm in 10 ml digestion buffer (6 μg/ml Liberase
TM (Roche), 5 U/ml DNaseI and 25 mM Hepes buffer
diluted in HBSS (all Sigma Aldrich, Missouri, USA)).
Following digestion, cell suspensions were passed through
a 70-μm cell strainer before being washed twice with
2-mM EDTA in HBSS. Myelin removal was performed
using myelin removal beads (Miltenyi Biotech, Cologne,
Germany) as per the manufacturer’s instructions using an
AutoMACS. Total cell number was determined using a
haemocytometer.
Flow cytometry
Cells were first incubated with 1-μl FcR block (Miltenyi)
per sample and then stained at 4 °C using the antibodies
listed in Additional file 2: Table S2. Samples were ana-
lysed using an LSR II or FACSAria I/III cytometer (BD
Biosciences) and FlowJo software (Tree Star).
Legendplex protein assay
Chemokine protein expression was measured using the
Legendplex assay (BioLegend, California, USA) as per
the manufacturer’s instructions. In brief, snap-frozen
brain tissue was homogenised in N-PER™ Neuronal Pro-
tein Extraction Reagent (Thermo Scientific) at a ratio of
10 ml per 1 g of tissue for 20 min on ice. Samples were
centrifuged at 10,000g for 10 min, and supernatant was
collected. Legendplex beads were incubated with whole
brain lysate for 2 h at 600 rpm on a plate shaker. Beads
were conjugated with streptavidin-PE for 30 min and
were washed twice prior to sample reading using BD
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LSRII flow cytometer. Samples were differentiated on
the basis of bead size and APC fluorescence. Protein
quantity was determined using SA-PE fluorescence cali-
brated to a standard curve. Limits of detection were 1.69
and 1.4 pg/ml for CCL2 and CXCL10, respectively.
Histology
Brain and skin samples were fixed in 10 % neutral buffered
formalin prior to processing and paraffin embedding. Pro-
cessing was performed using the Shandon Citadel 1000
automated tissue processor (Thermo scientific).
(i) Haematoxylin and eosin staining
Skin samples from treated mice were cut into 5-μm
sections and stained with haematoxylin and eosin
(H&E) to discern morphology.
(ii) CD3 T cell staining
Brains extracted from Aldara-treated mice were
formalin fixed and embedded in paraffin as
described. CD3 staining was performed, using a
rabbit anti-mouse CD3 antibody (Vector), by the
Veterinary Diagnostic Service Facility at the
University of Glasgow. Slides were cut from three
sequential regions through the mid-sagittal brain,
from four mice per group. Slides were blinded and
whole sections were counted for CD3.
(iii) Doublecortin (DCX) staining for neurogenesis
Seven micrometre sections were cut from formalin-
fixed brains from mice treated with Aldara or
control cream for 5 days. Sections were stained
with polyclonal goat anti-mouse DCX
(Santa Cruz Biotechnology, Texas, USA).
Slides were blinded, and the mean DCX counts
from three areas of the dentate gyrus of the
hippocampus were obtained per section.
Burrowing model of mouse behaviour
The assessment of burrowing behaviour was carried out
as previously described [24]. Briefly, groups were acclima-
tised overnight prior to baseline tests being performed.
Forty-eight hours later, mice were put on procedure and
were treated with Aldara or control cream as described
above. Burrowing tests were carried out on individually
caged mice for a 2-h time period, 4 h after Aldara treat-
ment, for three consecutive days.
Statistical analysis
All data were analysed using the Prism 4 software
(GraphPad, San Diego, CA, USA). Results are shown as
mean ± standard deviation (SD) unless stated otherwise.
Data were analysed using the unpaired two-tailed stu-
dent’s t test if two groups were compared. If more than
two groups were compared a one- or two-way ANOVA
was performed using the Bonferroni post-test. The figure
legends indicate which statistical test was used for each
graph. A p value of ≤0.05 was considered as statistically
significant.
Results
Aldara-treatment-induced psoriasis-like skin inflammation
is associated with a remote transcriptional response in
the brain
In this study, we performed a full genome microarray to
identify genes that may be differentially expressed in the
brain during the response to cutaneous Aldara treat-
ment. Mice treated with Aldara lost a significant amount
of body weight. This weight loss, shown in Fig. 1a, was
apparent after just one application and was most pro-
nounced between the third and fifth treatments. Aldara
treatment also induced psoriasis-like skin inflammation
in the mice, causing visible erythema and flakiness. The
psoriatic symptoms were confirmed in H&E sections
(Fig. 1b) taken 24 h after the fifth application of Aldara,
which show epidermal and dermal hyperplasia, keratosis
and marked skin thickening. To test the hypothesis that
peripheral inflammation induces inflammatory changes
in the brain, we comprehensively evaluated alterations in
gene expression in the brain in response to cutaneous
Aldara treatment using a full genome microarray ap-
proach. When analysed using GeneSpring GX software,
over 200 transcripts were significantly upregulated in the
brains of Aldara-treated mice compared with control
mice when a stringent fold-change cutoff of 3 or above
was applied. DAVID software was used to determine the
biological associations of the differentially expressed
genes by grouping them based on their function (Fig. 1c).
This analysis highlighted immune, inflammatory and
leukocyte-derived genes as being prominent within the
differentially expressed functional gene groupings. Inter-
estingly, amongst the top ten functional annotations,
chemokine signalling pathway, inflammation mediated
by chemokine and cytokine signalling pathway and
leukocyte transendothelial migration were enriched. As
they play a critical role in homeostatic and inflammatory
responses, both in the periphery and the CNS, we fo-
cused on chemokines as a potential mechanism of com-
munication between the periphery and the brain.
Amongst the subset of genes that were differentially
expressed between the two groups, seven chemokines
and one chemokine receptor were upregulated in the
brains of Aldara-treated mice, with a fold-change induc-
tion ranging between 3-fold and 25-fold. The relative ex-
pression levels of these eight genes, Ccl3, Ccl5, Cxcl13,
Cxcl9, Cxcl16, Ccl9, Cxcl10 and Ccr5, are displayed in
the heatmap in Fig. 1d, where they are presented in
order of their fold-change induction. Taken together,
these data suggest a remote upregulation of chemokine
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expression in the brain in response to localised cutane-
ous inflammatory responses.
Aldara treatment induces the upregulation of a subset of
chemokines in the brain, independent of a measurable
inflammatory profile in the circulation
To confirm the upregulated expression of chemokine
transcripts in the brains of Aldara-treated mice, and to
define the time course of induction, an independent ex-
periment was performed and chemokine gene expression
was analysed after one, three and five applications of
Aldara using QRT-PCR. To determine whether these
transcriptional changes arose in the brain independently
of residual signals from contaminating blood cells left
over from the perfusion, we also measured expression
levels in the peripheral blood cells from the treated mice.
At day 1, 24 h after topical Aldara treatment, Ccl3,
Cxcl10 and Ccr5 were significantly upregulated by PBL in
the Aldara-treated group compared to those isolated from
the control group (Fig. 2a, Additional file 3: Figure S1). At
day 3, Ccl3 and Ccl5 remained significantly elevated
by PBL from Aldara-treated mice; however, by day 5,
Ccl5 expression had returned to baseline. Only CCL3
remained significantly elevated by this time point
(Fig. 2a, Additional file 3: Figure S1). Thus, although
there is chemokine induction in the periphery, this
was largely restricted to the earlier time points.
In contrast to the mild chemokine response observed
in PBL, topical Aldara treatment resulted in a potent
and sustained chemokine induction in the brain. By day
3, all seven genes were significantly upregulated in the
brains of Aldara-treated mice (Fig. 2a). Strikingly, the ex-
pression of Ccl3, Ccl5 and Cxcl10 was increased almost
1000-fold at this time point. With the exception of Ccl3
and Cxcl10, the expression of all genes remained signifi-
cantly elevated at day 5. This was particularly notable
for Ccl5, the expression level of which was approxi-
mately 900-fold greater than the control. Importantly,
when comparing the fold induction in the brain to that
of the PBL, expression of all chemokine/chemokine re-
ceptor target genes was increased to a significantly
greater level in the brain than PBL at day 3 of the Aldara
model (Fig. 2a). Therefore, alterations to the transcrip-
tional profile of the brain were not a consequence of
A
C
B
D
Fig. 1 Aldara application, which causes a psoriasis-like skin inflammation, induces a remote transcriptional response in the brain. Mice were
treated with 80 mg of Aldara cream or control cream every 24 h for five consecutive days. a Mouse weights were recorded after each treatment.
Mice were euthanised 24 h after the final application, and b areas of treated skin were sectioned to 5 μm, stained with H&E and visualised at ×100
magnification using a light microscope. Epidermis [1], dermis [2], hair follicles [3], muscle [4], flaking of the stratum corneum [5] and epidermal
hyperplasia [6] are shown. Scale bar = 100 μm. Microarray analysis was performed on perfused whole brains. c DAVID analysis was used to identify
enriched biological pathways. d GeneSpring GX software was used to identify differentially expressed chemokine genes, which are presented on a
heatmap and shown in order of fold-change induction in the brain. n = 5 mice per group. Significance was measured using two-way ANOVA with
Bonferroni multiple comparison post-tests ***p ≤ 0.001
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residual peripheral blood contamination. Again, with
the exception of Ccl3 and Cxcl10, the fold-change in-
duction remains significantly greater in the brain than
the PBL at day 5. Ccr5 was the only gene that shows
a significantly greater fold-change induction in the
PBL than in the brain. However, this was only ob-
served on day 1 of the Aldara model. Although the
microarray data demonstrated a significant induction
of the gene encoding CXCL9, this appeared to be
below the detection limit of the QRT-PCR assay and
could not be validated in the PBL and the brain (data
not shown). It was therefore excluded from further ana-
lysis. Together, these data confirm that topical Aldara treat-
ment triggers a large increase in chemokine transcription
in the brain. Importantly, the response in the brain differs
both in magnitude and temporal patterning to that in the
PBL, with chemokine transcription remaining elevated
throughout the model.
To investigate whether the transcriptional response in
the brain was being driven by the presence of circulating
inflammatory cytokines, protein levels of IL-1β, IL-6, IL-17,
TNF-α, CCL2 and CCL3 were assessed at different time
points using luminex (Fig. 2b). IL-6 and CCL2 were the only
proteins to be significantly increased in the treatment group
compared with the control group, and this was only the case
after the first treatment. None of the other inflammatory cyto-
kines were significantly increased in the circulation at day 1,
day 3 or day 5. Collectively, the results in Fig. 2 demonstrate
that the brain response to Aldara treatment differs from the
peripheral blood response and does not appear to be associ-
ated with the expression of archetypal inflammatory cytokines
in the circulation.
A
B
Fig. 2 Aldara treatment induces a transcriptional brain response that is independent of a systemic peripheral response. Mice were treated with
80 mg Aldara cream or control cream every 24 h for one, three or five consecutive days. Mice were euthanised 24 h after the final application.
Cardiac puncture was performed to retrieve PBLs, and perfused brains were extracted. RNA was isolated from both tissues, and a QRT-PCR analysis
of the target chemokine genes was performed. b Luminex analysis was performed to determine the expression of classic inflammatory cytokines
in the plasma. n = 4 mice per group. Significance was measured using two-way ANOVA with Bonferroni multiple comparison post-tests. Additional
two-way ANOVA were used to compare the control and treated groups within each tissue (a). ***p ≤ 0.001 **p ≤ 0.01 *p ≤ 0.05
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Topically applied soluble IMQ induces chemokine
induction in the brain without causing overt skin
inflammation
There are reports that, along with the active TLR agonist,
imiquimod, Aldara cream contains another active compo-
nent: isostearic acid. This component of the vehicle is
thought to activate the inflammasome, induce keratino-
cyte cell death and stimulate the production of certain
pro-inflammatory cytokines [25]. To further explore
the mechanisms by which the brain-specific chemokine
response is induced following Aldara treatment, and to
discriminate between the activities of the isostearic acid
and IMQ, soluble IMQ was dissolved in isostearic acid-
free aqueous control cream and applied topically to the
dorsal skin. As before, mice treated with soluble IMQ
lost a significant amount of weight after the first two
treatments (Fig. 3a). Their weights remained signifi-
cantly lower than the control group throughout the
model. In contrast to Aldara treatment, topical soluble
IMQ treatment was not associated with significant skin
inflammation. The skin sections, examined after five appli-
cations of IMQ cream, do not show any overt signs of epi-
dermal hyperplasia, keratosis or erythema (Fig. 3b). These
data suggest that this aspect of the response may be inde-
pendent of TLR stimulation and reliant instead on the
actions of isostearic acid. Nonetheless, all chemokine/che-
mokine receptor target genes were significantly elevated
in the brain following topical IMQ treatment, independ-
ently of alterations in PBL (Fig. 3c). Of note, Ccl3, Ccl5
and Ccr5 presented with a fold-change induction upwards
A
C
B
Fig. 3 Topically applied imiquimod induces a transcriptional brain response but does not induce psoriasis-like skin inflammation. Mice were
treated with 80 mg of control cream containing 5 % imiquimod or control cream alone every 24 h for five consecutive days. a Mouse weights
were recorded after each treatment and are shown as percentage of initial weight, which was considered 100 %. Mice were euthanised 24 h after
the final application, and b areas of treated skin were sectioned to 5 μm, stained with H&E and visualised at ×100 magnification using a light
microscope. Epidermis [1], dermis [2], muscle [3] and hair follicles [4] are shown. Scale bar = 100 μm. PBL and perfused brains were collected, and
c QRT-PCR analysis of the target chemokine genes was performed. n = 5 mice per group. Significance was measured using two-way ANOVA with
Bonferroni multiple comparison post-tests. Individual unpaired student’s t tests were used to compare control vs treated within each tissue (c).
*** (###) = p ≤ 0.001 ** (##) = p ≤ 0.01 *(#) = p ≤ 0.05
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of 1000-fold. In this model, all genes encoding chemokine
ligands were downregulated in the PBL of treated mice
compared with control mice. With regard to all genes, the
fold-change induction in the brain following treatment
was significantly higher than the fold change in PBL.
These results demonstrate that, although the different ac-
tive components of Aldara may be responsible for driving
different aspects of the response, the actions of TLR ligand
IMQ alone are sufficient to induce the remote differential
chemokine response in the brain.
The differential chemokine response is dependent on
topical application, as systemically induced IMQ does not
induce a similar brain response
To determine whether the IMQ-induced response was
reliant on topical application to the skin, intraperitoneal
injections of IMQ were performed over the same period
of time. In contrast to the previous models, this treat-
ment did not induce any weight loss over the 5-day
period and the weights of the treated mice increased
gradually in line with the control group (Additional file 4:
Figure S2A). In stark contrast to the potent chemokine re-
sponse that was induced in the brain following topical
Aldara and/or IMQ application, only Ccl5 and Ccr5 were
significantly elevated in the brain (Additional file 4:
Figure S2B) and this induction was modest (approxi-
mately threefold and 1.2-fold, respectively). Further,
the induction of Ccl5 and Ccr5 expression in the brain
did not differ in magnitude to that of the PBL. These
findings clearly demonstrate that injecting IMQ systemic-
ally does not generate a similar response to the topical ap-
plication of IMQ. Thus, the induction of chemokines in
the brain is likely dependent, at least in part, on the initial
skin response.
Topical application and TLR ligation are essential for the
induction of chemokines in the brain
Having shown that the effects of cutaneous Aldara cream
treatment are mediated primarily through the actions of
the TLR ligand IMQ, we compared the response to a
model which generates a similar skin phenotype without
acting through TLRs. TPA is a chemical irritant which,
when applied to the dorsal skin, generates a similar skin
profile of epidermal and dermal hyperplasia and erythema.
However, this model does not act through TLRs and is
thus considered ‘sterile’. In contrast to both the Aldara
and topical IMQ models, topical TPA treatment did not
induce weight loss in the treated mice (Additional file 5:
Figure S3A). However, TPA did cause a similar skin in-
flammation to that observed following topical Aldara
treatment (Fig. 1b, Additional file 5: Figure S3B). This was
again characterised by skin thickening, epidermal and der-
mal hyperplasia, keratosis and erythema. Interestingly,
none of the chemokine/chemokine receptor target genes
were significantly altered in the brains or PBL of TPA-
treated mice (Additional file 5: Figure S3C). Furthermore,
in the plasma, only CCL2 was strongly and significantly
differentially expressed, and this induction was restricted
to day 1 (Additional file 5: Figure S3D). Circulating levels
of all other inflammatory cytokines and chemokines were
comparable between the treatment and control groups.
Together, these data suggest that the brain response that
occurs following topical Aldara treatment is dependent on
skin-specific TLR ligation and is not simply a generic re-
sponse to skin inflammation.
Aldara treatment induces the infiltration of monocytes/
macrophages into the brain
The most characterised role of chemokines is to coordin-
ate leukocyte migration [26]. Therefore, we used flow cy-
tometry to establish whether the transcriptional
upregulation of chemokines in the brain following topical
Aldara treatment was associated with an influx of leuko-
cytes from the periphery. To exclude resident microglia
that express intermediate levels of CD45, we only gated
on live, single, CD45hi cells (Additional file 6: Figure S4A).
The results show a significant increase in the number of
CD45hi cells present in the brains at both day 3 and day 5
following Aldara treatment (Additional file 6: Figure S4B).
Thus, topical Aldara treatment results in leukocyte re-
cruitment to the brain.
Monocytes are early responders to infection and have
been shown to infiltrate the brain in peripheral inflam-
matory models and in response to viral infections that
invade the central nervous system [44]. Interestingly,
several of the chemokine transcripts that are elevated in
the brain in response to topical Aldara treatment, spe-
cifically Ccl3, Ccl5 and Ccl9, are known to recruit
monocytes to sites of inflammation. In addition, protein
analysis from an independent experiment clearly demon-
strates that levels of CCL2, a classic monocyte chemo-
attractant, are also elevated in the brain following Aldara
treatment (Fig. 4a). As shown in Additional file 6:
Figure S4B, the treated brain appears to be devoid of
infiltrating leukocytes at day 1. This prompted us to
also analyse chemokine levels at two earlier time points,
4 and 12 h after treatment in order to capture the pro-
tein signal before and after leukocyte infiltration. Inter-
estingly, CCL2 was significantly elevated in the brain
from as early as 4 h following topical Aldara treatment
and prior to leukocyte infiltration (Fig. 4a) These data
suggest that CCL2 is likely to be produced by brain-
resident cells, rather than the infiltrating leukocytes
themselves.
Due to the enriched expression of monocyte chemoat-
tractants in the brain throughout the Aldara model, we
decided to use flow cytometry to determine whether the
influx of leukocytes to the brain at days 3 and 5 were
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due to monocyte accumulation. Figure 4b shows the
representative gating strategy used to identify neutro-
phils, monocytes and macrophages, from live, single,
CD45hiCD11b+ cells. Consistent with there being no evi-
dence of neutrophil chemoattractants being induced in
the brain following Aldara treatment, there was no sig-
nificant difference in the number of neutrophils between
control and treated brains at any time point, with all
counts being less than 600 per million cells (Fig. 4c).
There was a substantial increase in monocyte numbers,
defined as Ly6ChiLy6G−CD64− cells, in the brain at day
3 following Aldara treatment (Fig. 4c). Although it was
not statistically significant, a notably high number of
Ly6ChiCD64+ cells could also be detected in the brains
of treated mice at this time point. By day 5, the number
of monocytes and Ly6ChiCD64+ cells (population 2) ap-
peared to reduce, whilst the number of Ly6ClowCD64+ cells
(population 3) significantly increased (Fig. 4c). This would
suggest the infiltrating monocytes begin to differentiate
into tissue macrophages in the brain between day 3 and
day 5.
Aldara treatment triggers the infiltration of CD4+ T cells,
CD8+ T cells, NK cells and NK T cells into the brain
In addition to recruiting monocytes to sites of inflamma-
tion, CCL3 and CCL5 can also recruit populations of
lymphocytes, as can CXCL10, CXCL13 and CXCL16.
Thus, we next sought to characterise the full lymphocyte
repertoire in the brain at the three different time points.
To determine whether the transcription of lymphocyte
chemoattractants in the brain resulted in elevated pro-
tein production, we performed protein analysis of a key
T cell-recruiting chemokine, CXCL10. Again, in an at-
tempt to address whether the source of the chemokine
signature we report in this journal is brain-resident or
from infiltrating cells, we also analysed CXCL10 expres-
sion at 4 and 12 h after treatment. CXCL10 protein ex-
pression was significantly induced in the treated brain as
early as 4 h after cutaneous Aldara treatment when com-
pared with control brain (Fig. 5a). CXCL10 remained
significantly elevated throughout the model, with the
highest expression level at day 3. Whilst we cannot com-
ment on the source of the signal at day 3 and day 5,
when there appears to be a mixed population of brain-
resident cells and leukocyte infiltrate, we suggest it is
unlikely that CXCL10 is being produced by infiltrating
leukocytes at the earlier time points.
Figure 5b represents the gating strategy used to iden-
tify NK cells, NK T cells and CD4+ and CD8+ T cells,
which were pre-gated as live, single, CD11b− cells. Sur-
prisingly, although Cxcl13 expression was strongly in-
duced in the brain following treatment, there was no
A
B
Fig. 4 Aldara treatment induces the infiltration of monocytes, but not neutrophils, into the brain. Mice were treated with 80-mg Aldara cream or
control cream every 24 h for one, three or five consecutive days. Mice were euthanised 24 h following the final application. a Protein expression
of CCL2 in whole brain lysate was assessed in control and treated brains 4 h, 12 h, 1 day, 3 days and 5 days after treatment. b Perfused brains
were homogenised, and a single cell suspension was generated as described. Cells were labelled with fluorescent antibodies. CD45hiCD11b+ cells
were selected following dead cell exclusion and doublet exclusion, and representative gating strategy based on expression of Ly6C, Ly6G and CD64 is
shown. c Counts per million cells were generated using total cell counts and are shown for neutrophils, monocytes, differentiating monocytes
(population 2) and macrophages (population 3) at 1, 3 and 5 days following Aldara treatment. n = 4 mice per group. Significance was determined
using one- (a) or two-way (b, c) ANOVA with Bonferroni multiple comparison post-tests. Data presented in a were log transformed prior to statistical
analysis ****p < 0.0001 ***p ≤ 0.001 **p ≤ 0.01 *p ≤ 0.05
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evidence of a CD19+ B cell infiltrate at any of the time
points (data not shown). We saw little evidence of any
lymphocyte infiltration after the first treatment; however,
a significant increase in lymphocyte number was clear at
day 3 and day 5 post-treatment (Fig. 5c). TCRβ+ T cells
could be divided into the conventional CD4+ and CD8+
subsets. However, there was an additional population of
T cells that, rather than expressing the classic ‘double
negative’ T cell profile (i.e. CD4−CD8−), expressed low
levels of CD8 (CD8lo T cells) (Fig. 5b). These cells expressed
similar levels of both TCRβ and CD3 (data not shown).
The results show that NK cells, NK T cells, CD8lo T cells
and CD4+ T cells were all significantly increased in the
brains of Aldara-treated mice at day 3 (Fig. 5c). NK cells
were found to be the most abundant subset, with an aver-
age cell count just below 30,000 cells/106 cells in the treated
brains.
By day 5, numbers of NK cells, NK T cells and CD8lo
T cells remained significantly elevated in the brains of
treated mice (Fig. 5c). CD8+ T cell numbers did not be-
come significantly increased in the brain until day 5 of
the Aldara model, at which point the numbers of CD4 T
cells had returned to normal. Consistent with previous
studies showing that only activated T cells can enter the
brain, the vast majority of infiltrating T cells displayed
an effector/memory phenotype (Fig. 5b).
Together, these data characterise the significant
lymphoid infiltrate into the brain following cutaneous
Aldara treatment and implicate brain-resident cells as an
initial source of the T cell chemoattractant CXCL10.
Surprisingly, histological examination of CD3 expression
in the brain revealed that, rather than being localised to
perivascular cuffs, CD3+ cells were scattered throughout
the brain parenchyma (Fig. 6a). There was no anatomical
specificity to the infiltrating cells as they were present
throughout the parenchyma, as well as around specific
brain regions including the cerebellum, hippocampus
and circumventricular organs (CVOs). Consistent with
A
C
B
Fig. 5 Aldara treatment induces the infiltration of a number of lymphocyte subsets into the brain. Mice were treated with 80-mg Aldara cream or
control cream every 24 h for one, three or five consecutive days. Mice were euthanised 24 h following the final application. a Protein expression
of CXCL10 in whole brain lysate was assessed in control and treated brains 4 h, 12 h, 1 day, 3 days and 5 days after treatment. b Perfused brains
were homogenised, and a single cell suspension was generated as described. Cells were labelled with fluorescent antibodies. CD11b− cells were
selected following dead cell exclusion, and doublet exclusion and representative gating strategy based on expression of NK1.1, TCRb, CD4, CD8,
CD44 and CD62L is shown. c Counts per million cells were generated using total cell counts and are shown for NK cells, NK T cells, CD8lo T cells,
CD8+ T cells and CD4+ T cells at 1, 3 and 5 days following Aldara treatment. n = 4 mice per group. Significance was determined using one-
(a) or two-way (b, c) ANOVA with Bonferroni multiple comparison post-tests. Data shown in a were log transformed prior to statistical analysis
****p < 0.0001 ***p ≤ 0.001 **p ≤ 0.01
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the flow cytometry data, there were elevated numbers of
CD3+ cells at day 3 and day 5 following Aldara treat-
ment (Fig. 6b).
Cutaneous Aldara treatment causes a reduction in
neurogenesis and a suppression in burrowing activity
In order to determine the consequences of the Aldara-
induced transcriptional response in the brain, a molecular
output, neurogenesis, and a functional output, burrowing
behaviour, were assessed. Neuroinflammation has been
shown to have a negative effect on hippocampal neuro-
genesis during neurodegenerative diseases and following
the administration of LPS and inflammatory cytokines
[27–30]. In addition, there is a link between neurogenesis
and behaviour and some have reported that impaired
neurogenesis is associated with hippocampal cognitive
impairments, learning deficits and depressive-like symp-
toms [31–33]. The extent to which adult neurogenesis
was affected in this study was evaluated by counting the
number of doublecortin (DCX)-positive neurons in the
dentate gyrus of the hippocampus. DCX is a microtubule-
associated protein expressed by neuronal precursor cells
and immature neurons in embryonic and adult cortical
structures. As there is almost exclusive expression of DCX
in developing neurons, it has been used increasingly as a
marker for neurogenesis. Figure 7a shows representative
A
B
Fig. 6 Aldara treatment induces the infiltration of CD3+ cells into the brain. Mice were treated with 80-mg Aldara cream or control cream every
24 h for one, three or five consecutive days. Mice were euthanised 24 h following the final application. Perfused brains were fixed in formalin and
embedded in paraffin before being sectioned to 7 μm. a Three sections from each brain were stained for CD3. Representative sections of the
hippocampus and cerebellum are shown at ×400 magnification or ×100 magnification (□). Arrows indicate CD3+ cells. b Whole brain CD3+ infiltrates
were counted blind. n= 4 mice per group. Significance was determined using two-way ANOVA with Bonferroni multiple comparison
post-tests ***p ≤ 0.001
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staining of the dentate gyrus in both control and Aldara-
treated mice 24 h following the fifth application. The
amount of green stain suggested that Aldara treatment
caused a reduction in the number of DCX-positive neurons.
This was quantified by performing blinded cell counts,
which confirmed that Aldara treatment caused a significant
reduction in the quantity of neurogenesis (Fig. 7b). Our re-
sults are in agreement with previously published data sug-
gesting that inflammation can have a negative impact on
neurogenesis.
To examine possible behavioural correlates of increased
brain chemokine expression and T cell accumulation, we
next undertook behavioural analyses. As a behavioural
read-out, a basic burrowing model, in which mice burrow
for food pellets, was employed. The read-out is the
weight of pellets remaining in the burrowing tubes, as
opposed to that burrowed out of the tubes, after de-
fined periods of time. Burrowing is an innately reward-
ing activity in rodents; thus, this model indicates the
level of well-being in mice based on the amount of bur-
rowing activity that they participate in. As such, this
model has been used in various studies to identify a
behavioural output following inflammatory stimuli [34, 35].
Mice were acclimatised to the burrowing tubes prior to
treatment, and baseline tests were performed. Whilst the
baseline tests showed a wide range of burrowing activity,
the Aldara-treated and control groups began to separ-
ate after only one treatment. Figure 7c shows the
weight of pellets left in the tube following a 2-h testing
period after each application. The control mice had less
weight left in the tubes than treated mice, meaning that
burrowing activity was higher; whereas Aldara-treated
mice burrowed less with each application. Unfortu-
nately, this test could not be continued over the full
duration of the treatment period as it has been reported
that a decline in performance may occur due to over-
exposure to the procedure [36]. These custom-made
burrowing tubes were designed in such a way that they
did not interfere with the area of treated dorsal skin;
and it was observed throughout the model that the
treated mice displayed a normal range of physical ability,
for example climbing on the bars of the cage. Therefore,
this significantly impaired burrowing activity indicates that
cutaneous Aldara treatment has a negative effect on the
well-being of the mice.
Discussion
This study demonstrates that peripherally induced,
tissue-specific inflammation can ‘remotely’ alter the tran-
scriptional profile of the brain, independently of a simi-
lar response in the periphery. Topical Aldara treatment,
which induces a psoriasis-like skin inflammation, causes
A
C
B
Fig. 7 Aldara treatment causes a reduction of adult neurogenesis and a suppression of burrowing activity. Mice were treated with 80-mg Aldara
cream or control cream every 24 h for one, three or five consecutive days and were euthanised 24 h after the final application. a Brains were
isolated from mice after five applications of Aldara and were formalin fixed and paraffin embedded. Seven micrometre sections were cut and
immunostained for DCX and were visualised using a fluorescent microscope at ×400 magnification b Blind counts of three areas of the dentate
gyrus were performed for each section to determine the quantity of new neurons. c Burrowing activity was determined 4 h after one, two and
three treatments of Aldara cream. Data are presented as the weight of material left in the burrowing tube after a 2-h test period. n = 5 mice per
group for neurogenesis (mean of three areas from 11/12 sections per group), n = 10 mice per group for burrowing assessment. Significance was
determined using unpaired student’s t test (b) or two-way ANOVA with Bonferroni multiple comparison post-tests (c). ***p ≤ 0.001 **p ≤ 0.01
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the upregulation of a number of genes in the brain, in-
cluding seven inflammatory chemokines and one che-
mokine receptor, a response that was not mimicked by
PBL. This response peaks following the third application
but persists beyond the fifth application suggesting a
prolonged expression in the brain. That this response
was also seen with topically applied reconstituted IMQ,
but not with a sterile model of skin inflammation,
implicates peripheral TLR ligation as an important mech-
anism in the induction of this response. In addition, the
lack of a brain response following an I.P. injection of recon-
stituted IMQ suggests that the localised skin response is
also an important factor in driving the brain response.
The use of reconstituted IMQ yielded an interesting
result in that a significant brain response was observed
in the absence of an overt skin inflammation, which is
important when considering the mechanisms of commu-
nication between the periphery and the brain. Although
the lack of cutaneous inflammation is reportedly due to
the omission of isostearic acid [25], it is difficult to hy-
pothesise how the effects of peripheral inflammation are
being transmitted to the brain without the generation of
a local inflammatory response or circulating inflamma-
tory cytokines. It is also notable that neither induction
of a ‘sterile’ cutaneous inflammatory response nor intra-
peritoneal administration of IMQ resulted in the gener-
ation of a brain response in our study. One possibility
that might unite these disparate observations is that the
communication between the inflamed skin and the brain is
not driven by inflammatory agents but by direct ligation of
TLRs on sensory nerves within the skin which then trans-
mit a response to the brain inducing transcriptional
changes associated with ‘sickness behaviour’. A number of
studies have shown TLR expression on peripheral nerves
[37–39], and a further series of experiments is planned by
our lab to specifically address this issue. An alternative hy-
pothesis is that tissue-resident myeloid cells, or other
leukocytes exposed to the inflamed environment in the
skin, could transmit the signal to the brain directly, by mi-
grating through the circulation to the brain. Alternatively,
they could transmit inflammatory signals indirectly, by
causing damage to peripheral nerves that is then sensed by
the brain. Whilst we do not feel this provides a mechanistic
explanation for our observations, due to the fact that TPA
treatment induces a potent inflammatory response in the
skin and is not associated with chemokine upregulation in
the brain, further studies would be required to investigate
this potential route of immune-to-brain communication.
Strikingly, in addition to triggering the expression of
chemokines in the brain, topical Aldara treatment was
associated with a sizable recruitment of several leu-
kocyte populations to the brain, including CD4+ T cells,
CD8+ T cells, NK cells, NK T cells and monocytes. On
day 3, the monocyte populations in the brain were
Ly6C+CD64- and Ly6C+CD64+, whereas by day 5, they
were predominantly Ly6C+CD64+ monocytes and
Ly6C-CD64+ macrophages. This is likely indicative of
monocyte to macrophage differentiation. Although we
cannot directly link enhanced chemokine production to
leukocyte recruitment, the chemokine profile in the brain
was highly specific to the cell populations recruited.
Several groups have shown that chemokine induction
in the brain can induce leukocyte infiltration, both under
neuroinflammatory conditions [16, 40–43], in response
to peripheral inflammation [44] and during CNS viral in-
fection [16, 45]. The brain specific chemokine profile
that is triggered following topical Aldara treatment bears
a notable resemblance to the array of chemokines that
are induced in the brain following encephalitic virus in-
fection [16]. Indeed, the leukocyte populations that infil-
trate the brain following Aldara treatment: monocytes,
effector memory T cells, NK cells and NKT cells, are
populations that play a prominent role during viral in-
fection and are often crucial for pathogen clearance.
Furthermore, as would be expected during viral enceph-
alitis, IMQ, the active component of Aldara, stimulates
TLR7 to mimic a viral response. Thus, in response to
TLR7 ligation in the periphery, the brain may specifically
produce monocyte and lymphocyte chemoattractants to
recruit the appropriate populations required to protect
the brain against a potential viral infection.
The infiltration of immune cells into the brain following
a remote immune challenge is both surprising and inter-
esting. The generation of a cellular brain response follow-
ing peripheral inflammation could indicate the presence
of a protective surveillance mechanism initiated when a
potential CNS insult is anticipated to ‘prime’ the brain.
However, further studies would need to be performed be-
fore we could begin to unpick the role of these infiltrating
cells, and their fate beyond the time points examined.
A key question regarding this response relates to the
temporal relationship between chemokine induction in
the brain and leukocyte recruitment, as infiltrating leuko-
cytes may either have responded to chemokines made in
the brain prior to their recruitment, or may in fact have
contributed to the expression of the detected chemokines.
However, at least two key inflammatory chemokines,
CXCL10 and CCL2, are upregulated in the brain at the
protein level by 4 h respectively following topical Aldara
treatment, whereas immune cells are not recruited into
the brain until 72 h post-treatment. This leads us to
propose that chemokine production within the brain paren-
chyma precedes, and is likely to be at least partially respon-
sible for, the subsequent recruitment of immune cells.
In addition to immune cell infiltration, chemokines are
also implicated in a number of neuromodulatory processes,
including neurotransmission, development and neurogen-
esis [11, 46–48], indicating that changes in chemokine
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expression could disrupt essential homeostatic events in
the CNS [49]. In this study, we have been able to link per-
ipheral cutaneous inflammation with two relevant func-
tional outputs: an impairment in adult neurogenesis at the
dentate gyrus and a reduction in burrowing activity of mice,
a behaviour that has been shown to be a sensitive rep-
resentation of neuropsychiatric imbalance in a number
of inflammatory CNS disease models [24, 50]. It is
worth noting that whilst food pellets were a convenient
material to be used in large quantities, it is assumed that
this model is not appetite-dependent and mice were not
‘food rationed’ at any time. Nevertheless, it remains pos-
sible that an additional contribution to the lack of burrow-
ing seen in the inflamed mice may come from a
generalised lack of interest in food as a consequence of an
impaired sense of well-being. Of course, to fully character-
ise the behavioural deficits in response to Aldara treat-
ment, and to associate these with neuropsychiatric
conditions, more sophisticated, impairment-specific be-
havioural tests should be performed. Nonetheless, our
data suggest that inflammation generated at distant
sites has the potential to negatively influence homeo-
static brain function.
Conclusions
In summary, this study shows that peripheral, tissue-
specific skin inflammation can remotely induce both tran-
scriptional and functional responses in the brain, and it
implicates inflammatory chemokines as potential media-
tors of the brain response to peripheral inflammation.
This study has provided a comprehensive characterisation
of the peripherally triggered, infiltrating leukocytes in the
brain, which have the potential to exert a profound effect
on CNS homeostasis. Our findings highlight the sensitivity
of the CNS to peripheral changes and offer a correlative
insight into how chronic inflammatory diseases are com-
monly associated with the onset of neuropsychiatric co-
morbidities. With further investigation, it is hoped that
the intricate mechanisms can be unravelled and key media-
tors identified, thus allowing for better treatment strategies
for these co-morbid disorders.
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